225 related articles for article (PubMed ID: 12570367)
1. Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells.
Zhuang L; Wai JS; Embrey MW; Fisher TE; Egbertson MS; Payne LS; Guare JP; Vacca JP; Hazuda DJ; Felock PJ; Wolfe AL; Stillmock KA; Witmer MV; Moyer G; Schleif WA; Gabryelski LJ; Leonard YM; Lynch JJ; Michelson SR; Young SD
J Med Chem; 2003 Feb; 46(4):453-6. PubMed ID: 12570367
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of 5-(1-H or 1-alkyl-5-oxopyrrolidin-3-yl)-8-hydroxy-[1,6]-naphthyridine-7-carboxamide inhibitors of HIV-1 integrase.
Melamed JY; Egbertson MS; Varga S; Vacca JP; Moyer G; Gabryelski L; Felock PJ; Stillmock KA; Witmer MV; Schleif W; Hazuda DJ; Leonard Y; Jin L; Ellis JD; Young SD
Bioorg Med Chem Lett; 2008 Oct; 18(19):5307-10. PubMed ID: 18774711
[TBL] [Abstract][Full Text] [Related]
3. A series of 5-aminosubstituted 4-fluorobenzyl-8-hydroxy-[1,6]naphthyridine-7-carboxamide HIV-1 integrase inhibitors.
Guare JP; Wai JS; Gomez RP; Anthony NJ; Jolly SM; Cortes AR; Vacca JP; Felock PJ; Stillmock KA; Schleif WA; Moyer G; Gabryelski LJ; Jin L; Chen IW; Hazuda DJ; Young SD
Bioorg Med Chem Lett; 2006 Jun; 16(11):2900-4. PubMed ID: 16554152
[TBL] [Abstract][Full Text] [Related]
4. 1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position.
Johns BA; Weatherhead JG; Allen SH; Thompson JB; Garvey EP; Foster SA; Jeffrey JL; Miller WH
Bioorg Med Chem Lett; 2009 Mar; 19(6):1807-10. PubMed ID: 19217284
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and antiviral activity of 7-benzyl-4-hydroxy-1,5-naphthyridin-2(1H)-one HIV integrase inhibitors.
Boros EE; Edwards CE; Foster SA; Fuji M; Fujiwara T; Garvey EP; Golden PL; Hazen RJ; Jeffrey JL; Johns BA; Kawasuji T; Kiyama R; Koble CS; Kurose N; Miller WH; Mote AL; Murai H; Sato A; Thompson JB; Woodward MC; Yoshinaga T
J Med Chem; 2009 May; 52(9):2754-61. PubMed ID: 19374386
[TBL] [Abstract][Full Text] [Related]
6. The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore.
Johns BA; Weatherhead JG; Allen SH; Thompson JB; Garvey EP; Foster SA; Jeffrey JL; Miller WH
Bioorg Med Chem Lett; 2009 Mar; 19(6):1802-6. PubMed ID: 19217781
[TBL] [Abstract][Full Text] [Related]
7. A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells.
Embrey MW; Wai JS; Funk TW; Homnick CF; Perlow DS; Young SD; Vacca JP; Hazuda DJ; Felock PJ; Stillmock KA; Witmer MV; Moyer G; Schleif WA; Gabryelski LJ; Jin L; Chen IW; Ellis JD; Wong BK; Lin JH; Leonard YM; Tsou NN; Zhuang L
Bioorg Med Chem Lett; 2005 Oct; 15(20):4550-4. PubMed ID: 16102965
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of novel N-hydroxy-dihydronaphthyridinones as potent and orally bioavailable HIV-1 integrase inhibitors.
Johnson TW; Tanis SP; Butler SL; Dalvie D; Delisle DM; Dress KR; Flahive EJ; Hu Q; Kuehler JE; Kuki A; Liu W; McClellan GA; Peng Q; Plewe MB; Richardson PF; Smith GL; Solowiej J; Tran KT; Wang H; Yu X; Zhang J; Zhu H
J Med Chem; 2011 May; 54(9):3393-417. PubMed ID: 21446745
[TBL] [Abstract][Full Text] [Related]
9. A potent and orally active HIV-1 integrase inhibitor.
Egbertson MS; Moritz HM; Melamed JY; Han W; Perlow DS; Kuo MS; Embrey M; Vacca JP; Zrada MM; Cortes AR; Wallace A; Leonard Y; Hazuda DJ; Miller MD; Felock PJ; Stillmock KA; Witmer MV; Schleif W; Gabryelski LJ; Moyer G; Ellis JD; Jin L; Xu W; Braun MP; Kassahun K; Tsou NN; Young SD
Bioorg Med Chem Lett; 2007 Mar; 17(5):1392-8. PubMed ID: 17194584
[TBL] [Abstract][Full Text] [Related]
10. Design and optimization of tricyclic phtalimide analogues as novel inhibitors of HIV-1 integrase.
Verschueren WG; Dierynck I; Amssoms KI; Hu L; Boonants PM; Pille GM; Daeyaert FF; Hertogs K; Surleraux DL; Wigerinck PB
J Med Chem; 2005 Mar; 48(6):1930-40. PubMed ID: 15771437
[TBL] [Abstract][Full Text] [Related]
11. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase.
Hazuda DJ; Anthony NJ; Gomez RP; Jolly SM; Wai JS; Zhuang L; Fisher TE; Embrey M; Guare JP; Egbertson MS; Vacca JP; Huff JR; Felock PJ; Witmer MV; Stillmock KA; Danovich R; Grobler J; Miller MD; Espeseth AS; Jin L; Chen IW; Lin JH; Kassahun K; Ellis JD; Wong BK; Xu W; Pearson PG; Schleif WA; Cortese R; Emini E; Summa V; Holloway MK; Young SD
Proc Natl Acad Sci U S A; 2004 Aug; 101(31):11233-8. PubMed ID: 15277684
[TBL] [Abstract][Full Text] [Related]
12. Exploration of novel thiobarbituric acid-, rhodanine- and thiohydantoin-based HIV-1 integrase inhibitors.
Rajamaki S; Innitzer A; Falciani C; Tintori C; Christ F; Witvrouw M; Debyser Z; Massa S; Botta M
Bioorg Med Chem Lett; 2009 Jul; 19(13):3615-8. PubMed ID: 19447621
[TBL] [Abstract][Full Text] [Related]
13. A platform for designing HIV integrase inhibitors. Part 1: 2-hydroxy-3-heteroaryl acrylic acid derivatives as novel HIV integrase inhibitor and modeling of hydrophilic and hydrophobic pharmacophores.
Kawasuji T; Yoshinaga T; Sato A; Yodo M; Fujiwara T; Kiyama R
Bioorg Med Chem; 2006 Dec; 14(24):8430-45. PubMed ID: 17010623
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, antiviral, and anti-HIV-1 integrase activities of 3-aroyl-1,1-dioxo-1,4,2-benzodithiazines.
Brzozowski Z; Saczewski F; Sanchez T; Kuo CL; Gdaniec M; Neamati N
Bioorg Med Chem; 2004 Jul; 12(13):3663-72. PubMed ID: 15186851
[TBL] [Abstract][Full Text] [Related]
15. Dihydroxypyridopyrazine-1,6-dione HIV-1 integrase inhibitors.
Wai JS; Kim B; Fisher TE; Zhuang L; Embrey MW; Williams PD; Staas DD; Culberson C; Lyle TA; Vacca JP; Hazuda DJ; Felock PJ; Schleif WA; Gabryelski LJ; Jin L; Chen IW; Ellis JD; Mallai R; Young SD
Bioorg Med Chem Lett; 2007 Oct; 17(20):5595-9. PubMed ID: 17822898
[TBL] [Abstract][Full Text] [Related]
16. Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties.
Zeng LF; Wang Y; Kazemi R; Xu S; Xu ZL; Sanchez TW; Yang LM; Debnath B; Odde S; Xie H; Zheng YT; Ding J; Neamati N; Long YQ
J Med Chem; 2012 Nov; 55(22):9492-509. PubMed ID: 23098137
[TBL] [Abstract][Full Text] [Related]
17. New 2-arylnaphthalenediols and triol inhibitors of HIV-1 integrase--discovery of a new polyhydroxylated antiviral agent.
Maurin C; Lion C; Bailly F; Touati N; Vezin H; Mbemba G; Mouscadet JF; Debyser Z; Witvrouw M; Cotelle P
Bioorg Med Chem; 2010 Jul; 18(14):5194-201. PubMed ID: 20541944
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors.
Barreca ML; Ferro S; Rao A; De Luca L; Zappalà M; Monforte AM; Debyser Z; Witvrouw M; Chimirri A
J Med Chem; 2005 Nov; 48(22):7084-8. PubMed ID: 16250669
[TBL] [Abstract][Full Text] [Related]
19. Rationally designed dual inhibitors of HIV reverse transcriptase and integrase.
Wang Z; Bennett EM; Wilson DJ; Salomon C; Vince R
J Med Chem; 2007 Jul; 50(15):3416-9. PubMed ID: 17608468
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of substituted 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamides, novel HIV-1 integrase inhibitors.
Langford HM; Williams PD; Homnick CF; Vacca JP; Felock PJ; Stillmock KA; Witmer MV; Hazuda DJ; Gabryelski LJ; Schleif WA
Bioorg Med Chem Lett; 2008 Jan; 18(2):721-5. PubMed ID: 18078751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
